-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Propagermanium in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Focal Segmental Glomerulosclerosis (FSGS) - Drugs In Development, 2023’, provides an overview of the Focal Segmental Glomerulosclerosis (FSGS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Drugs In Development, 2023’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Propagermanium in Focal Segmental Glomerulosclerosis (FSGS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Propagermanium in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Propagermanium (DMX-200) as an adjunct therapy with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SAR-444881 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:BND-22 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – propagermanium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry propagermanium Drug Details Propagermanium (DMX-200) as an adjunct therapy with irbesartan is under development...
-
Product Insights
Immunochemistry Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Spot test kits intended generally for rapid diagnosis, with immediate results, through immuno assays. Some of the tests carried out using immunochemistry rapid test include rabies virus test, allergenic food proteins, and enteric infection. The immunochemistry rapid tests and POC pipeline market research report provides comprehensive information about the immunochemistry rapid tests and POC pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Product Insights
Chronic Obstructive Pulmonary Disease (COPD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic Obstructive Pulmonary Disease (COPD) symptoms include inability to completely breathe out air from the lungs leading to shortness of breath. Other symptoms include cough, fatigue, and chest pain. The COPD pipeline drugs market research report provides an analysis of the COPD drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest...